2024 Preview: Are We There Yet?
After a year in which investor sentiment went from bad to worse, 2024 has started on a more positive note. Last week’s JP Morgan conference saw a flurry of partnership and acquisition announcements, building on the last couple of weeks of December which saw 2023’s deal making end with a bang. If the end is […]
Themes from BIO Europe
There’s far too much to share in one blog post, but there were three areas that I wanted to summarise as I think they’re a good indicator of the current state of the biopharma market and give us an insight into what we can expect from pharma and biotech in 2024. 1. Dealmaking Increasing competition […]
In Case You Missed It: Three Things We Learned In Our World Preview Webinar
You may have read the report, you may have pondered the infographic, but the best way to really get under the skin of the Evaluate World Preview report is to join the webinar. As well as sharing the highlights of the data from the report, the webinar gave our presenters a chance to really discuss […]
Five Top Takeaways from BIO International 2023
A couple of weeks ago, we saw the return of BIO International to Boston for the first time since 2018. Since Boston is Evaluate’s home turf in the US, we headed to the gigantic Boston Convention Center to join 19,000 pharma, biotech and investment experts for four days of meetings, presentations, networking shindigs and sore […]
In Case You Missed It: Three Things We Learned In Our Gene Editing Webinar
Missed our gene editing webinar? Fear not! Here are a few of the highlights from our panel of experts which included Verve Therapeutics’ CEO, Sekar Kathiresan as well as our home-grown specialists. And if that’s not enough, the webinar is available on demand. Gene editing is a hot topic right now. With the first Pdufa […]
Five Questions About the Future of Gene Editing
Gene editing has been in and out of the news since Crispr hit the headlines a decade ago. It’s been anything from the next big thing to a borderline miracle to a potential menace. Is it just going through the same growing pains as any new technology in the pharma industry? Or is it fundamentally […]
In Case You Missed It: Three Things We Learned From the Evaluate Vantage 2023 Preview Webinar
Missed out latest webinar? Fear not, here are three things we learned from the 2023 Preview discussion. And the webinar is available on demand now. It is now officially too late to say “Happy new year” to people you’ve not seen since December, but it’s not quite too late to be looking ahead to what […]
More in Hope than Expectation: Biopharma in 2023
Few people are expecting biopharma to stage a spectacular comeback in 2023 but what can we reasonably hope for – and when? I joined the world of biopharma in 2022 and it seems I didn’t pick a vintage year. M&A activity was weak, share prices plummeted and IPOs were all but non-existent. However, I have […]
What to expect from JP Morgan 2023
The real start to the biopharma year, the JP Morgan Healthcare Conference, is nearly upon us. As the holidays fade into memory – along with a pretty rough 2022 – what will this bellwether of the industry bring? I caught up with one of Evaluate’s VP consultants, Vinay Bhaskar, who’ll be in San Francisco as […]
Medtech in 2028: Suffering or Celebrating a COVID Hangover?
We’ve extended our forecasts out to 2028 and in our latest report, we take a look at what’s in store for the medtech market in the next few years. It seems obvious to say that Covid had a massive impact on the medtech industry but being obvious doesn’t stop the statement being true. Several […]
